Immunology Target Discovery for Rheumatoid Arthritis

The project ran over 8 months and covered data harmonization, model development, validation, and deployment.The team included AI engineers, bioinformatics specialists, and domain experts working together to build a scalable decision-support system for R&D.

The client is a global biopharmaceutical company focused on immunology and advanced therapeutic research.Their goal was to accelerate the discovery of novel targets for rheumatoid arthritis by leveraging existing multi-omics and expression datasets more effectively.

The R&D pipeline was constrained by fragmented data and disconnected evaluation processes.Researchers had to manually cross-reference gene expression data, omics datasets, and scientific literature, which slowed discovery and introduced subjectivity into decision-making.

During implementation, it became clear that the issue was not just data volume, but lack of a unified evaluation framework.Scientific and commercial assessments were performed separately, making it difficult to prioritize targets in a consistent and scalable way.

Nextigent AI developed the Target:Disease Pairing AI Agent as a structured, multi-layered evaluation system.The agent analyzed multi-omics data, expression profiles, translational evidence, and market intelligence to generate a ranked list of targets.Each target was scored across two key dimensions:

• scientific strength
• business opportunity

Large language models were used to mine literature and patents, identifying emerging research signals that would be difficult to capture manually.The system was deployed in a secure cloud environment, with interactive dashboards and APIs that allowed researchers to explore results, compare targets, and adjust weighting dynamically.

The platform is being extended to additional therapeutic areas, including metabolic and neurodegenerative diseases.Further development focuses on predictive modeling and automated identification of partnership opportunities.